Improving ophthalmology trial outcomes through diversity, equity & inclusion

Lexitas

DEDICATED TO OPHTHALMICS

Almost 20%

of new therapeutics show differences in exposure and/or response across racial and ethnic groups

---

Ramamoorthy A, Pacanowski M, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: Review of recently approved drugs. *Clinical Pharmacology & Therapeutics*. 2015;97(3):263-273



HOWEVER, IN 2020

75%

of the clinical trial population

in the US was white, whereas whites composed only 62% of the national population

Jones N, Marks R, Ramirez R, Rios-Vargas M. Improved Race and Ethnicity Measures Reveal U.S. Population Is Much More Multiracial. The United States Census Bureau. Published August 12, 2021. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html

Sharma A, Palaniappan L. Improving diversity in medical research. Nature Reviews Disease Primers. 2021;7(1)



WORLDWIDE

76%

of trial participants in 2020 were white, although 75% of the world's population lives in Asia and sub-Saharan Africa

Jones N, Marks R, Ramirez R, Rios-Vargas M. Improved Race and Ethnicity Measures Reveal U.S. Population Is Much More Multiracial. The United States Census Bureau. Published August 12, 2021. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html

Sharma A, Palaniappan L. Improving diversity in medical research. Nature Reviews Disease Primers. 2021;7(1)

The FDA recommends that trial sponsors and CROs create frameworks that ensure the data they capture is representative of various populations prior to applying for FDA approval.

Achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities.

FDA Commissioner Robert Califf

FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials. FDA. Published April 20, 2022. https://www.fda.gov/news-events/press-announcements/fda-takes-important-steps-increase-racial-and-ethnic-diversity-clinical-trials

4 STEPS

to ensuring more diverse, equitable, and inclusive clinical trials

1. Establish representative diversity in staffing

Employees from different geographic and underrepresented groups provide variety on the design and execution of clinical research studies, as well as uncover nuances and biases that may otherwise be overlooked.

Patients often prefer to be under the care of physicians and staff who understand and even share their backgrounds.

2. Partner with diverse investigators, sites, and patient advocacy organizations

Building long-term relationships and partnerships with stakeholders who are familiar with the needs of underserved communities is essential to creating and steering studies that can effectively recruit and retain trial participants.

3. Incorporate new investigators and sites in clinical research

A site network should ensure inclusion of the different geographies in which patients live so that more patients can access clinical research from their own physicians and in their own communities.

Sponsors and CROs must evolve, grow, and enable the pool of sites and investigators trained and active in clinical research.

4. Partner with the right ophthalmics product development partner

Look for ophthalmics product development partners that truly believe in and embrace diversity in their own hiring practices, as they are the ones most likely to build it into trial design as well.

This leads to the types of trials that both investigators and patients want to participate in, resulting in higher enrollment and better retention.

Want to learn more about successfully managing your ophthalmic trial?

CONTACT US

Lexitas Pharma Services, Inc.
(919) 205-0012
www.lexitas.com